Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials

By sjmartinez • April 18, 2024

Merola JF, Armstrong A, Khattri S, Paek SY, Padilla B, Yue C, Photowala H, Kaplan B, Kristensen LE. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18. PMID: 38632977.

Tags: Biologics, Dermatology, interleukin-23, psoriatic arthritis, Publications, risankizumab

Benefits of Earlier Apremilast Initiation in Patients with Psoriasis and Limited Skin Involvement: Results from a Real-World Retrospective Study

Armstrong A, Strober B, Gisondi P, Orroth KK, Cordey M, Kent ST, Deignan C, Jardon S, Hernandez RK, Brookhart MA, Stein Gold L. Benefits of[...]

Upadacitinib for Alopecia: Current Evidence and Clinical Insights

Stirrat T, Thakker S, Bejugam D, Goh C, Lipner SR. Upadacitinib for Alopecia: Current Evidence and Clinical Insights. Skin Appendage Disord. 2025 Aug;11(4):320-334. doi: 10.1159/000544868.[...]

Hot Topics: Exploring Artificial Intelligence and Inflammatory Memory in the Management of Psoriatic Diseases

Shucheng H, Armstrong AW, Eidsmo L, Poddubnyy D. Hot Topics: Exploring Artificial Intelligence and Inflammatory Memory in the Management of Psoriatic Diseases. J Rheumatol. 2025[...]